Screening for symptoms of COVID-19 and self-quarantine are good at preventing sick people from spreading the coronavirus. But more and more evidence is suggesting that people without symptoms are spreading the virus too. Monica Gandhi, an infectious diseases physician and researcher at the University of California, San Francisco, explains what is known about asymptomatic spread and why she thinks it may be a big part of what is driving the pandemic.
What Does It Mean To Be Asymptomatic?
SARS-CoV-2 – the virus that causes COVID-19 – can produce a range of clinical manifestations.
Some people who are infected never develop any symptoms at all. These patients are considered true asymptomatic cases.
When people do get sick from the coronavirus, it takes on average five days and as many as two weeks to develop symptoms that can range from very mild to extremely dangerous. The time between initial infection and the first symptoms is called the pre-symptomatic phase.
As an infectious disease physician, when I hear about asymptomatic spread of SARS-CoV-2, I think of a person who doesn’t have symptoms at the moment they give the virus to someone else. It doesn’t matter whether they are a true asymptomatic case or just pre-symptomatic; the public health risk is the same.
How many people are asymptomatic?
Estimates of the proportion of true asymptomatic cases – those who are infected and never develop symptoms – range from 18% to over 80%. The reasons for the huge range in estimates are still unclear, but some studies are better than others.
The most accurate way to determine the rate of asymptomatic cases is to test people regardless of whether or not they have symptoms – an approach called universal mass testing – and track them over time to see if they develop symptoms later. A recent mass testing campaign in San Francisco found that 53% of infected patients were asymptomatic when first tested and 42% stayed asymptomatic over the next two weeks.
Another recent paper compared the evidence from 16 studies and estimated the overall rate of asymptomatic infection to be 40%-45%. This is in line with the San Francisco finding, but the studies sampled were of various quality and size and likely include some pre-symptomatic cases.
Though none of these studies is perfect, a lot of evidence supports a true asymptomatic rate of around 40%, plus some addition fraction of patients who are pre-symptomatic.
How can asymptomatic people spread the coronavirus?
Compared to most other viral infections, SARS-CoV-2 produces an unusually high level of viral particles in the upper respiratory tract – specifically the nose and mouth. When those viral particles escape into the environment, that is called viral shedding.
The location of the shedding is also important. SARS-CoV – the virus that caused the SARS epidemic in 2003 – does not shed very much from the nose and mouth. It replicates deep in the lungs. Since SARS-CoV-2 is present in high numbers in a person’s nose and mouth, it is that much easier for the virus to escape into the environment.
When people cough or talk, they spray droplets of saliva and mucus into the air. Since SARS-CoV-2 sheds so heavily in the nose and mouth, these droplets are likely how people without symptoms are spreading the virus.
How much asymptomatic spread is happening?
Public health experts don’t know exactly how much spread is caused by asymptomatic or pre-symptomatic patients. But there are some telling hints that it is a major driver of this pandemic.
An early modeling estimate suggested that 80% of infections could be attributed to spread from undocumented cases. Presumably the undocumented patients were asymptomatic or had only extremely mild symptoms. Though interesting, the researchers made a lot of assumptions in that model so it is hard to judge the accuracy of that prediction.
A study looking at outbreaks in Ningbo, China, found that people without symptoms spread the virus as easily as those with symptoms. If half of all infected people are without symptoms at any point in time, and those people can transmit SARS-CoV-2 as easily as symptomatic patients, it is safe to assume a huge percentage of spread comes from people without symptoms.
Even without knowing the exact numbers, the Centers for Disease Control and Prevention believes that transmission from people without symptoms is a major contributor to the rapid spread of SARS-CoV-2 around the world.
What can we do to limit asymptomatic spread?
Any time a virus can be spread by people without symptoms, you have to turn to preventative measures.
Social distancing measures and lockdowns work, but have large economic and social repercussions. These were necessary when epidemiologists didn’t know how the virus was spreading, but now we know it sheds at high quantities from the upper respiratory tract.
On April 3, the CDC recommended that all members of the public wear facial coverings when outside of the house and around others. The World Health Organization finally followed suit and recommended universal public masking on June 5.
At this point, no one knows exactly how many cases of COVID-19 are from asymptomatic spread. But I and many other infectious diseases researchers are convinced that it is playing a major role in this pandemic. Wearing a mask and practicing social distancing can prevent asymptomatic spread and help reduce the harm from this dangerous virus until we get a vaccine.
ABOUT THE AUTHOR
Monica Gandhi MD, MPH is Professor of Medicine and Associate Division Chief (Clinical Operations/ Education) of the Division of HIV, Infectious Diseases, and Global Medicine at UCSF/ San Francisco General Hospital. She also serves as the medical director of the HIV Clinic at SFGH (“Ward 86”). Dr. Gandhi completed her M.D. at Harvard Medical School and then came to UCSF in 1996 for residency training in Internal Medicine. After her residency, Dr. Gandhi completed a fellowship in Infectious Diseases and a postdoctoral fellowship at the Center for AIDS Prevention Studies, both at UCSF. She also obtained a Masters in Public Health from Berkeley in 2001 with a focus on Epidemiology and Biostatistics. Dr. Gandhi’s current research program is on identifying low-cost solutions to measuring antiretroviral levels in resource-poor settings, such as determining drug levels in hair samples. Dr. Gandhi also works on pre-exposure prophylaxis and treatment strategies for HIV infection in women. Dr. Gandhi co-directed the “Communicable Diseases of Global Health Importance” course in the Global Health Sciences Masters program from 2008-2015, and serves as the overall Education Director of the HIV, ID and Global Medicine Division. She also served as the principal investigator of an R24 mentoring grant from the NIH focused on nurturing early career investigators of diversity in HIV research, is the co-Director for the Center for AIDS Research (CFAR) Mentoring Program, and is the Chair of the Advisory Board for the UCSF Building Interdisciplinary Research Careers in Women’s Health (BIRCWH). She directs the HIV/ID Consult Service at San Francisco General Hospital (SFGH) and attends on the inpatient Infectious Diseases consult service. Dr. Gandhi receives funding from the National Institutes of Health for HIV-related research. This article is published courtesy of The Conversation.